Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03028584
Other study ID # UW16029
Secondary ID P30CA0145202016-
Status Completed
Phase
First received
Last updated
Start date September 11, 2017
Est. completion date March 23, 2018

Study information

Verified date October 2018
Source University of Wisconsin, Madison
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a two part observational study evaluating the feasibility of implementing an EHR-based model within a community oncology practice.


Description:

Part 1: The research team will use a sociotechnical work systems model, developed by researchers at the University of Wisconsin (UW) Systems Engineering Initiative for Patience Safety (SEIPS), to guide analysis of the work system barriers and facilitators to implementing an EHR-based care planning model in community oncology practice, collected from direct observations.

Part 2: The research team will measure reach/maintenance (percentage of survivors with EHR-based survivorship care plans (SCPs) over a 9-month time period) and impact (pre/post survey of patient satisfaction and perceived care coordination).


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 23, 2018
Est. primary completion date February 28, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Clinicians: Provide cancer care to BrCa, CRCa or PrCa

- Clinicians: Are a physician, advanced practice practitioner, nurse, or equivalent

- Patients: Have a diagnosis of breast, colorectal, or prostate cancer for which and EHR-based SCP will be provided

- Patients: Have been treated with curative intent (e.g. surgery, chemotherapy and/or radiation therapy) for a Stage 1-3 cancer diagnosis

- Patients: Have received some part of active cancer treatment

- Patients: Have complete active treatment (defined as surgery, chemotherapy, and/or radiation therapy). HER2-based and endocrine therapies may be ongoing and do NOT need to have been completed

Exclusion Criteria:

- Unable to complete or unwilling to answer questions in English

- Patients: Received all active cancer treatment elsewhere (e.g. "observation - only" patients)

- Patients: Have metastatic cancer

Study Design


Intervention

Behavioral:
Survey
Subjects (cancer patients and clinicians) will complete up to 2 surveys.

Locations

Country Name City State
United States UW Cancer Center at ProHealth Care Waukesha Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
University of Wisconsin, Madison National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary EHR-based SCPs and care planning Asses whether barriers to EHR-based SCPs and care planning have been mitigated, based on clinician survey. Up to 2 years
Secondary Feasibility of providing EHR-based care planning, measured by SCP provision rates Measured by SCP provision rates (percentage of survivors with EHR-based SCPs) Up to 2 years
Secondary Feasibility of providing EHR-based care planning, measured by the EHR Measured by survivor access to SCPs, per the EHR Up to 2 years
Secondary Self-reported change in satisfaction, using survey The impact of providing EHR-based care planning measured in change of satisfaction with perceived care coordination (assessed prior to and at 4 weeks after SCP provision) Up to 2 years
Secondary Impact of providing EHR-based care planning Measured by reported SCP usability, usefulness, and content (assessed prior to and at 4 weeks after SCP provision) Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A